We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 10/1/2022

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

story of the week

Journal Scan / Research · August 02, 2022

Safety and Efficacy of Rituximab vs Dimethyl Fumarate in Patients With Relapsing–Remitting MS or Clinically Isolated Syndrome in Sweden

The Lancet Neurology




This abstract is available on the publisher's site.

Access this abstract now   Full Text Available for ClinicalKey Subscribers

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Neurology
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
Lancet Neurol 2022 Aug 01;21(8)693-703, A Svenningsson, T Frisell, J Burman, J Salzer, K Fink, S Hallberg, J Hambraeus, M Axelsson, FA Nimer, P Sundström, M Gunnarsson, R Johansson, J Mellergård, I Rosenstein, A Ayad, I Sjöblom, A Risedal, P de Flon, E Gilland, J Lindeberg, F Shawket, F Piehl, J Lycke

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading